nach oben

International Urogynecology Journal

Erschienen in:

26.03.2021 | Review Article

Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology

verfasst von: Pierre-Luc Dequirez, Xavier Biardeau

Erschienen in: International Urogynecology Journal | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Using similar methodologies and outcome measures is crucial to allow pertinent literature reviews and meta-analyses. Therefore, this scoping review aims to compare methodologies of randomized clinical trials (RCTs) assessing the efficacy of third-line therapies to treat non-neurogenic OAB: intradetrusor onabotulinumtoxinA (BoNTA) injections, sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS).

Methods

A literature search was conducted using the PubMed search database. Using filters, the search was limited to RCTs conducted on humans and written in English or French since 2000 which evaluated BoNTA injections, SNM and/or PTNS. RCTs focusing on pediatric or neurogenic OAB were excluded. For each included RCT, methodology was assessed using a standardized form investigating the study design, clinical outcomes and urodynamic outcomes. Inclusion criteria, sex ratio, blinding strategies, treatment arms, primary outcomes and delays for reevaluation were assessed. Availability of clinical and urodynamic outcomes was reported at baseline, 3 months and 6 months.

Results

Thirty-one RCTs were included in the final synthesis. The most frequent main outcome measure was change in the number of urinary incontinence episodes in 35.5% and in the number of voids per day in 25.8%. Bladder diaries were lacking in 12.9%, 32.3% and 80.1% at baseline, 3 and 6 months, respectively, while 26% of studies reported the results of urodynamic studies at any point.

Conclusion

Heterogeneity in study designs and data collection was pointed out between RCTs assessing the efficacy of third-line therapies to treat non-neurogenic OAB. We therefore advocate for the development of specific research guidelines focusing on OAB-related therapies.

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. https://doi.org/10.1016/s0090-4295(02)02243-4.CrossRefPubMed

Overactive Bladder (OAB) Guideline - American Urological Association. Accessed August 1, 2020. https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline#x2907.

Marcelissen T, Cornu J-N, Antunes-Lopes T, et al. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? Eur Urol Focus. 2018;4(5):760–7. https://doi.org/10.1016/j.euf.2018.05.004.CrossRefPubMed

Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1.CrossRefPubMedPubMedCentral

Yokoyama O, Honda M, Yamanishi T, et al. OnabotulinumtoxinA (botulinum toxin type a) for the treatment of Japanese patients with overactive bladder and urinary incontinence: results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). Int J Urol. 2020;27(3):227–34. https://doi.org/10.1111/iju.14176.CrossRefPubMedPubMedCentral

Herschorn S, Kohan A, Aliotta P, et al. The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin naïve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. J Urol. 2017;198(1):167–75. https://doi.org/10.1016/j.juro.2017.01.069.CrossRefPubMed

Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2S):S216–23. https://doi.org/10.1016/j.juro.2016.10.109.CrossRefPubMed

Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. https://doi.org/10.1016/j.eururo.2013.04.001.CrossRefPubMed

Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3):520–9. https://doi.org/10.1016/j.eururo.2011.10.028.CrossRefPubMed

10.

Altaweel W, Mokhtar A, Rabah DM. Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder. Urol Ann. 2011;3(2):66–70. https://doi.org/10.4103/0974-7796.82170.CrossRefPubMedPubMedCentral

11.

Kanagarajah P, Ayyathurai R, Caruso DJ, Gomez C, Gousse AE. Role of botulinum toxin-a in refractory idiopathic overactive bladder patients without detrusor overactivity. Int Urol Nephrol. 2012;44(1):91–7. https://doi.org/10.1007/s11255-011-9979-9.CrossRefPubMed

12.

Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556–62. https://doi.org/10.1002/nau.21021.CrossRefPubMed

13.

Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22. https://doi.org/10.1016/j.juro.2010.08.021.CrossRefPubMed

14.

Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-a for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6. https://doi.org/10.1016/j.juro.2007.01.130.CrossRefPubMed

15.

Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-a injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int. 2009;103(11):1509–15. https://doi.org/10.1111/j.1464-410X.2009.08402.x.CrossRefPubMed

16.

Cohen BL, Barboglio P, Rodriguez D, Gousse AE. Preliminary results of a dose-finding study for botulinum toxin-a in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn. 2009;28(3):205–8. https://doi.org/10.1002/nau.20611.CrossRefPubMed

17.

Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74. https://doi.org/10.1001/jama.2016.14617.CrossRefPubMedPubMedCentral

18.

Amundsen CL, Komesu YM, Chermansky C, et al. Two-year outcomes of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74(1):66–73. https://doi.org/10.1016/j.eururo.2018.02.011.CrossRefPubMedPubMedCentral

19.

Abdelwahab O, Sherif H, Soliman T, Elbarky I, Eshazly A. Efficacy of botulinum toxin type a 100 units versus 200 units for treatment of refractory idiopathic overactive bladder. Int Braz J Urol. 2015;41(6):1132–40. https://doi.org/10.1590/S1677-5538.IBJU.2014.0221.CrossRefPubMedPubMedCentral

20.

Gousse AE, Kanagarajah P, Ayyathurai R, Handa P, Dabas N, Gomez CS. Repeat intradetrusor injections of onabotulinum toxin a for refractory idiopathic overactive bladder patients: a single-center experience. Female Pelvic Med Reconstr Surg. 2011;17(5):253–7. https://doi.org/10.1097/SPV.0b013e31822f816f.CrossRefPubMed

21.

Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum a injection. J Urol. 2008;180(1):217–22. https://doi.org/10.1016/j.juro.2008.03.028.CrossRefPubMedPubMedCentral

22.

Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type a versus posterior tibial nerve stimulation. Can J Urol. 2017;24(3):8838–46.PubMed

23.

Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum a toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15. https://doi.org/10.1016/j.juro.2009.01.117.CrossRefPubMedPubMedCentral

24.

Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30. https://doi.org/10.1002/nau.22544.CrossRefPubMed

25.

Zhang Y, Zhang P, Tian X, et al. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device. World J Urol. 2019;37(11):2481–92. https://doi.org/10.1007/s00345-019-02698-7.CrossRefPubMed

26.

Tang H, Chen J, Wang Y, Yu T, Guo C, Liao X. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial. Urol J. 2014;11(4):1800–5.PubMed

27.

O’Reilly BA, Fynes M, Achtari C, et al. A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):497–502. https://doi.org/10.1007/s00192-007-0481-y.CrossRefPubMed

28.

Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn. 2010;29(7):1267–71. https://doi.org/10.1002/nau.20823.CrossRefPubMed

29.

Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6. https://doi.org/10.1016/j.juro.2010.06.113.CrossRefPubMed

30.

Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61. https://doi.org/10.1016/j.juro.2009.05.045.CrossRefPubMed

31.

Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Investig. 2013;75(4):230–4. https://doi.org/10.1159/000350216.CrossRef

32.

Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecol Obstet Investig. 2013;75(1):46–52. https://doi.org/10.1159/000343756.CrossRef

33.

Preyer O, Umek W, Laml T, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6. https://doi.org/10.1016/j.ejogrb.2015.05.014.CrossRefPubMed

34.

Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol. 2018;44(1):102–8. https://doi.org/10.1590/S1677-5538.IBJU.2016.0611.CrossRefPubMedPubMedCentral

35.

Ramírez-García I, Blanco-Ratto L, Kauffmann S, Carralero-Martínez A, Sánchez E. Gel. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: randomized control trial. Neurourol Urodyn. 2019;38(1):261–8. https://doi.org/10.1002/nau.23843.CrossRefPubMed

36.

Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2017;43(1):121–6. https://doi.org/10.1590/S1677-5538.IBJU.2015.0719.CrossRefPubMedPubMedCentral

37.

Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32(1):179–84. https://doi.org/10.1007/s00345-013-1112-5.CrossRefPubMed

38.

Manríquez V, Guzmán R, Naser M, et al. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016;196:6–10. https://doi.org/10.1016/j.ejogrb.2015.09.020.CrossRefPubMed

39.

Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69(2):324–33. https://doi.org/10.1016/j.eururo.2015.07.071.CrossRefPubMed

40.

Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev 2016;12:CD010098. https://doi.org/10.1002/14651858.CD010098.pub4.

41.

Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stöhrer M. Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the standardisation Committee of the International Continence Society. Neurourol Urodyn. 1998;17(3):249–53. https://doi.org/10.1002/(sici)1520-6777(1998)17:3<249::aid-nau9>3.0.co;2-d.CrossRefPubMed

42.

Ahmed HU, Akin O, Coleman JA, et al. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer. BJU Int. 2012;109(11):1636–47. https://doi.org/10.1111/j.1464-410X.2011.10633.x.CrossRefPubMed

Titel: Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology
verfasst von: Pierre-Luc Dequirez
Xavier Biardeau
Publikationsdatum: 26.03.2021
Verlag: Springer International Publishing
Erschienen in: International Urogynecology Journal / Ausgabe 10/2021
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-021-04688-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology

Abstract

Introduction and hypothesis

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Blutdrucksenkung könnte Uterusmyome verhindern

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Gynäkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction and hypothesis

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Commentary on ‘Can effective supervised pelvic floor muscle training be provided by primary care nurses? A randomized controlled trial’

Treatment of urinary incontinence: a critical appraisal of clinical practice guidelines with the AGREE II instrument

Letter to the editor: Single-incision slings for the treatment of stress urinary incontinence: efficacy and adverse effects at 10-year follow-up

Contemporary trends for urological training and management of stress urinary incontinence in Ireland

Adult female urinary incontinence guidelines: a systematic review of evaluation guidelines across clinical specialties

Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Blutdrucksenkung könnte Uterusmyome verhindern

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Gynäkologie